Bayer's Q2 Beat Reshapes the Investment Debate — But a September Court Date Still Holds the Pen
Published on 08/06/2026 at 04:31 | Redaktion boerse-global.de
The bull case for Bayer is no longer a leap of faith. When the Leverkusen-based conglomerate published its second-quarter numbers on Tuesday, the market's reaction was swift and unusually uniform: a wave of price-target hikes from the major investment banks, all pointing in the same direction. The shares responded in kind, closing Wednesday at 49.40 euros, up 2.28 percent on the day — still roughly 8.3 percent shy of the 52-week high of 53.86 euros touched in early July.
What changed? The headline figure tells much of the story. Adjusted earnings per share came in at 0.95 euros for the quarter, comfortably ahead of the 0.77 euros analysts had penciled in. EBITDA before special items rose 1.9 percent to 2.144 billion euros, again beating the consensus estimate of 1.94 billion. Group revenue, adjusted for currency and portfolio effects, grew 2.2 percent to 10.872 billion euros.
Crop Science Carries the Quarter While Pharma Sends Mixed Signals
The engine room was unmistakable. Crop Science delivered EBITDA of 902 million euros for the quarter, a 30.2 percent jump that accounted for most of the upside surprise. The division's revenue rose 4 percent to 4.9 billion euros, powered by a 13 percent gain in the glyphosate business and a 17 percent leap in soybean products.
Pharma told a more complicated story. Division earnings slipped 3.6 percent to 1.52 billion euros, and while revenue inched up just 1 percent to 4.5 billion euros, the composition beneath that headline number reveals a portfolio in transition. The growth franchises are firing: Nubeqa surged 50 percent to 820 million euros in quarterly sales, while the newer drugs Nubeqa and Kerendia posted gains of 64 percent and 83 percent respectively in the half-year figures. The legacy blockbusters, however, are bleeding. Xarelto and Eylea fell 42 percent and 33 percent respectively — the unmistakable signature of patent expiries grinding through the portfolio.
Should investors sell immediately? Or is it worth buying Bayer?
Analysts Rush to Reprice the Stock
The sell-side response was remarkable for its consistency. Goldman Sachs' James Quigley lifted his target from 62.50 to 63.50 euros with a "Buy" rating, citing the strong financial performance, the value embedded in the pharma business, progress on glyphosate litigation and what he sees as a shrinking conglomerate discount. UBS's Matthew Weston raised his target from 52 to 62 euros, also with a "Buy," noting that the core operating result beat consensus by 10 percent — and that this optimism rests entirely on the operational story, since there was no fresh news on the glyphosate front. JPMorgan moved to "Overweight" with a target of 61 euros, up from 50. The DZ Bank lifted its fair value from 54 to 60 euros and kept its "Buy" recommendation.
The lone dissenting voice belongs to Jefferies, which held its target at 46 euros with a "Hold" — leaving the analyst target range spanning from 46 to 63.50 euros, a spread that itself speaks to how much uncertainty still surrounds the stock.
Debt Comes Down Faster Than Expected
The balance sheet is quietly becoming a second pillar of the bull case. Net financial debt stood at 33.647 billion euros at the end of June — the secondary figures put it at 33.6 billion — but management now expects that to fall to between 29 and 30 billion euros by year-end, thanks to a 3 billion euro capital injection from Apollo. That is meaningfully better than the 32 to 33 billion euros previously guided. The improvement matters: leverage has long been flagged by analysts as a persistent drag on the equity story, and the faster-than-expected deleveraging gives the bears one less argument.
Not everything is moving in the right direction. Free cash flow slipped deeper into negative territory, to minus 2.7 billion euros from minus 1.4 billion a year earlier, dragged down by litigation-related payments. The half-year figures show group revenue up 3 percent on an adjusted basis to 24.3 billion euros, with core EPS at 3.66 euros and EBITDA before special items at 6.6 billion euros, up 7 percent.
The Legal Calendar Still Governs the Risk Premium
For all the operational momentum, the courtroom remains the ultimate arbiter of the stock's trajectory. A Missouri court has pushed back the final hearing on the proposed 7.25 billion US dollar glyphosate class-action settlement from August 19 to September 10, 2026. The delay stems from the time needed to process opt-out requests — plaintiffs who choose to walk away from the deal could still alter its final scope.
Bayer at a turning point? This analysis reveals what investors need to know now.
There is, however, a fresh tailwind from the legal front. In late June, the US Supreme Court ruled that claims over a missing cancer warning on Roundup are not permissible under federal law — a decision that strengthens Bayer's hand in the remaining glyphosate cases. The Erickson PCB case, meanwhile, still awaits a Washington Supreme Court ruling on the admissibility of punitive damages, a decision that could set a precedent for similar claims.
CEO Bill Anderson confirmed during the earnings call that the US glyphosate business will be consolidated into a new standalone unit called "Ruveon." A full breakup of the conglomerate remains a strategic option, management said, but nothing imminent.
The picture that emerges is of a company where the operational and legal narratives are finally converging. The September 10 hearing now stands as the next critical waypoint — the moment when investors will learn whether the settlement holds together, and with it, whether the analysts' newly raised targets have a legal foundation to match their financial one.
Ad
Bayer Stock: New Analysis - 6 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
